Meptazinol
| 300px | |
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-3-(3-ethyl-1-methylazepan-3-yl)phenol
|
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Legal status | |
| Dependence liability |
Low |
| Routes of administration |
Oral, IM, IV |
| Pharmacokinetic data | |
| Metabolism | The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours. |
| Biological half-life | Half-Life (1.4–4 hours). |
| Excretion | The drug is rapidly metabolised to the glucuronide, and mostly excreted in the urine. |
| Identifiers | |
| CAS Number | 59263-76-2  |
| ATC code | N02AX05 (WHO) |
| PubChem | CID: 41049 |
| ChemSpider | 37469  |
| UNII | 18Y7S5JKZD |
| KEGG | D08182 |
| ChEMBL | CHEMBL314437 |
| Chemical data | |
| Formula | C15H23NO |
| Molecular mass | 233.34922 g/mol |
|
|
|
|
| (what is this?) (verify) |
|
Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s.[1] Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics (childbirth). A partial µ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full µ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.[2]
It does not appear in the US Controlled Substances Act 1970; it may or may not be regulated as an analogue of controlled relatives such as proheptazine (ACSCN 9643)
References
- ↑ US patent 4197239, Cavalla JF, Shepherd RG, White AC, "Hexahydroazepine, Piperidine and Pyrrolidine Derivatives", issued 1980-04-08, assigned to Wyeth
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
External links
- Meptazinol at the US National Library of Medicine Medical Subject Headings (MeSH)
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
